From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis - 14/11/13
Abstract |
Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.
Le texte complet de cet article est disponible en PDF.Key words : biologics, cyclosporine, immunosuppressive therapy, inactivated vaccine, live vaccine, methotrexate, vaccine administration, vaccine counseling
Abbreviations used : CDC, HBV, HPV, IBD, IL, MMR, TNF
Plan
Funding sources: None. |
|
Disclosure: Dr Van Voorhees has served on advisory boards for Amgen, Abbvie, Genentech, Warner Chilcott, Janssen, Novartis, and LEO Pharma; has been an investigator and consultant for Amgen and Abbvie; and has been a speaker for Amgen, Abbvie, and Janssen Biotech. She also has owned stock and stock options for Merck. Drs Wine-Lee, Keller, Wilck, and Gluckman have no conflicts of interest to declare. |
Vol 69 - N° 6
P. 1003-1013 - décembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?